• Something wrong with this record ?

A Novel Non-Immunoglobulin (non-Ig)/BCL6 Translocation in Diffuse Large B-Cell Lymphoma Involving Chromosome 10q11.21 Loci and Review on Clinical Consequences of BCL6 Rearrangements

M. Jarosova, E. Kriegova, P. Schneiderova, R. Fillerova, V. Prochazka, M. Mikesova, P. Flodr, K. Indrak, T. Papajik,

. 2016 ; 22 (2) : 233-43. [pub] 20150830

Language English Country Netherlands

Document type Case Reports, Journal Article, Research Support, Non-U.S. Gov't, Review

Persistent link   https://www.medvik.cz/link/bmc17001036

BCL6 rearrangements (3q27) are the most common chromosomal abnormalities in diffuse large B-cell lymphoma (DLBCL), with numerous immunoglobulin (Ig) and non-Ig genes as partners. In DLBCL, the translocations occur predominantly in the "major breakpoint region" encompassing the first noncoding exon and a part of the first intron of BCL6; few cases with "alternative breakpoint cluster" located 245-285 kb 5' BCL6 were also described. The regulatory sequences of known Ig and non-Ig partners replace the 5' untranslated region of the BCL6 in the same transcriptional orientation. Contrary to Ig/BCL6 fusions typical by high BCL6 gene expression, in non-Ig/BCL6 translocations were observed unexpectedly low BCL6 mRNA levels. From the clinical point of view, the survival rate of DLBCL patients with non-Ig partners is inferior to those with Ig/BCL6 translocations, suggesting that non-Ig/BCL6 fusion is a poor prognostic indicator. Hereby we provide comprehensive information about known non-Ig translocation partners and clinical consequences of BCL6 rearrangements in DLBCL. Moreover, we describe a novel reciprocal translocation t(3;10) in refractory patient with DLBCL with the breaking points at 5' untranslated region of BCL6 and 5' untranslated region of the RASGEF1A gene on chromosome 10q11.21 loci; this rearrangement was associated with low BCL6 and RASGEF1A gene expressions. Our patient harbouring dual chromosomal rearrangement involving BCL2 and BCL6 genes relapsed three-times and died soon; thus, further supporting the notion that non-Ig/BCL6 fusion is a poor prognostic indicator of DLBCL. There is evidence of prognostic value of BCL6 rearrangements also in rituximab era.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17001036
003      
CZ-PrNML
005      
20170621083354.0
007      
ta
008      
170103s2016 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s12253-015-9972-1 $2 doi
024    7_
$a 10.1007/s12253-015-9972-1 $2 doi
035    __
$a (PubMed)26319027
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Jarosova, Marie $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc and the University Hospital Olomouc, Hnevotinska 3, 77900, Olomouc, Czech Republic. marie.jarosova@fnol.cz.
245    12
$a A Novel Non-Immunoglobulin (non-Ig)/BCL6 Translocation in Diffuse Large B-Cell Lymphoma Involving Chromosome 10q11.21 Loci and Review on Clinical Consequences of BCL6 Rearrangements / $c M. Jarosova, E. Kriegova, P. Schneiderova, R. Fillerova, V. Prochazka, M. Mikesova, P. Flodr, K. Indrak, T. Papajik,
520    9_
$a BCL6 rearrangements (3q27) are the most common chromosomal abnormalities in diffuse large B-cell lymphoma (DLBCL), with numerous immunoglobulin (Ig) and non-Ig genes as partners. In DLBCL, the translocations occur predominantly in the "major breakpoint region" encompassing the first noncoding exon and a part of the first intron of BCL6; few cases with "alternative breakpoint cluster" located 245-285 kb 5' BCL6 were also described. The regulatory sequences of known Ig and non-Ig partners replace the 5' untranslated region of the BCL6 in the same transcriptional orientation. Contrary to Ig/BCL6 fusions typical by high BCL6 gene expression, in non-Ig/BCL6 translocations were observed unexpectedly low BCL6 mRNA levels. From the clinical point of view, the survival rate of DLBCL patients with non-Ig partners is inferior to those with Ig/BCL6 translocations, suggesting that non-Ig/BCL6 fusion is a poor prognostic indicator. Hereby we provide comprehensive information about known non-Ig translocation partners and clinical consequences of BCL6 rearrangements in DLBCL. Moreover, we describe a novel reciprocal translocation t(3;10) in refractory patient with DLBCL with the breaking points at 5' untranslated region of BCL6 and 5' untranslated region of the RASGEF1A gene on chromosome 10q11.21 loci; this rearrangement was associated with low BCL6 and RASGEF1A gene expressions. Our patient harbouring dual chromosomal rearrangement involving BCL2 and BCL6 genes relapsed three-times and died soon; thus, further supporting the notion that non-Ig/BCL6 fusion is a poor prognostic indicator of DLBCL. There is evidence of prognostic value of BCL6 rearrangements also in rituximab era.
650    _2
$a lidské chromozomy, pár 10 $x genetika $7 D002879
650    12
$a genová přestavba $7 D015321
650    _2
$a lidé $7 D006801
650    _2
$a difúzní velkobuněčný B-lymfom $x genetika $7 D016403
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a prognóza $7 D011379
650    _2
$a protoonkogenní proteiny c-bcl-6 $x genetika $7 D051560
650    _2
$a translokace genetická $x genetika $7 D014178
655    _2
$a kazuistiky $7 D002363
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a Kriegova, Eva $u Department of Immunology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Hnevotinska 3, 77900, Olomouc, Czech Republic.
700    1_
$a Schneiderova, Petra $u Department of Immunology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Hnevotinska 3, 77900, Olomouc, Czech Republic.
700    1_
$a Fillerova, Regina $u Department of Immunology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Hnevotinska 3, 77900, Olomouc, Czech Republic.
700    1_
$a Procházka, Vít $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc and the University Hospital Olomouc, Hnevotinska 3, 77900, Olomouc, Czech Republic. $7 xx0143822
700    1_
$a Mikesova, Michaela $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc and the University Hospital Olomouc, Hnevotinska 3, 77900, Olomouc, Czech Republic.
700    1_
$a Flodr, Patrik, $u Department of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, Palacky University Olomouc and the University Hospital Olomouc, Hnevotinska 3, 77900, Olomouc, Czech Republic. $d 1975- $7 nlk20030127444
700    1_
$a Indrak, Karel $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc and the University Hospital Olomouc, Hnevotinska 3, 77900, Olomouc, Czech Republic.
700    1_
$a Papajík, Tomáš, $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc and the University Hospital Olomouc, Hnevotinska 3, 77900, Olomouc, Czech Republic. $d 1967- $7 xx0060566
773    0_
$w MED00180530 $t Pathology oncology research POR $x 1532-2807 $g Roč. 22, č. 2 (2016), s. 233-43
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26319027 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170103 $b ABA008
991    __
$a 20170621083813 $b ABA008
999    __
$a ok $b bmc $g 1180176 $s 961603
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 22 $c 2 $d 233-43 $e 20150830 $i 1532-2807 $m Pathology oncology research $n Pathol Oncol Res $x MED00180530
LZP    __
$a Pubmed-20170103
Back

Find record

Citation metrics

Archiving options